以岭药业(002603.SZ)获得“盐酸美金刚”化学原料药上市申请批准

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary, Wanyuan Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of Memantine Hydrochloride, a chemical raw material drug [1] Group 1 - The approved drug, Memantine Hydrochloride, is a voltage-dependent, moderate-affinity non-competitive NMDA receptor antagonist [1] - Memantine Hydrochloride can block pathological increases in glutamate concentration that lead to neuronal damage [1] - The drug is indicated for the treatment of moderate to severe Alzheimer's disease [1]